The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

As cancer research is threatened, we must engage in political advocacy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The views expressed here are those of George Weiner, not those of the University of Iowa, where he is on the faculty, or the National Cancer Institute Board of Scientific Advisors, of which he is a member.

As cancer clinicians, we spend years learning how to think objectively and rationally when supporting patients who have responded to a cancer diagnosis with anger and fear. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
George J. Weiner, MD
Professor of internal medicine-hematology, oncology, and blood & marrow transplantation, Professor of pharmaceutical sciences and experimental therapeutics, CE Block Chair of Cancer Research, Director emeritus, University of Iowa Holden Comprehensive Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Health innovation and health equity: Ensuring technologies advance resilience, justice, and compassionate care

Technological innovations are often hailed as transformative tools capable of revolutionizing healthcare. From gene editing for conditions like sickle cell disease to AI predicting hospital readmissions, to telemedicine expanding healthcare access, these advancements have the potential to change the way we treat diseases. 
By Jamillah Hoy-Rosas
In the Archives

In 1990, “political oncologist” Helene Brown predicted the future. Did she get it right?

When Helene Brown, a cancer control pioneer who jokingly described herself as “the first in a long line of political oncologists,” delivered the keynote address at the Oncology Nursing Society annual meeting in 1990, she set forth bold predictions for the ensuing 20 years of the field: appointments conducted over “computerphone,” major genetic breakthroughs, and universal healthcare.
By Katie Goldberg
Byline
George J. Weiner, MD
Professor of internal medicine-hematology, oncology, and blood & marrow transplantation, Professor of pharmaceutical sciences and experimental therapeutics, CE Block Chair of Cancer Research, Director emeritus, University of Iowa Holden Comprehensive Cancer Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account